With the direct participation of 600 corporations and shocking levels of secrecy, the Office of the U.S. Trade Representative (USTR) is rushing to complete the Trans-Pacific Partnership (TPP). Branded as a trade agreement (yawn) by its corporate proponents, TPP largely has evaded public and congressional scrutiny since negotiations were launched in 2008 by the George W. Bush administration.
But trade is the least of it. Only two of TPP’s 26 chapters actually have to do with trade. The rest is about new enforceable corporate rights and privileges and constraints on government regulation. This includes new extensions of price-raising drug patent monopolies, corporate rights to attack government drug formulary pricing plans, safeguards to facilitate job offshoring and new corporate controls over natural resources.
